SYNGENE384.00

Syngene International Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹15,471 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations910.1853.5916.9789.7891.0943.71,018.0874.5910.6917.11,036.5736.0
Other Income21.629.316.118.116.518.318.917.715.415.422.225.3
Total Income931.7882.8933.0807.8907.5962.01,036.9892.2926.0932.51,058.7761.3
Expenses
+ Cost of Materials Consumed241.8240.3172.1168.0230.8241.9228.1239.5227.5220.9223.3178.2
+ Changes in Inventories25.4-2.930.765.55.8-4.56.9-21.911.08.59.8-4.8
+ Employee Benefit Expense225.5220.9226.9229.9251.5249.5253.0261.7275.0267.4300.8259.1
+ Finance Costs13.010.812.911.713.112.415.911.613.211.912.19.6
+ Depreciation & Amortisation104.6108.1111.1106.9110.9108.7106.1111.2116.5113.7111.5112.2
+ Other Expenses163.3163.7170.3156.5158.1173.2186.4188.8197.6211.1199.2212.7
Total Expenses773.6740.9724.0738.5770.2781.2796.4790.9840.8833.5856.7767.0
EBITDA254.1231.5316.9169.8244.8283.6343.6206.4199.5209.2303.490.8
EBIT149.5123.4205.862.9133.9174.9237.595.283.095.5191.9-21.4
Profit
PBT before Exceptional Items158.1141.9209.069.3137.3180.8240.5101.385.299.0202.0-5.7
+ Exceptional Items-7.4-3.70.032.00.00.00.00.00.0-70.6-6.0-13.5
Pretax Income150.7138.2209.0101.3137.3180.8240.5101.385.228.4196.0-19.2
+ Current Tax29.824.542.419.227.444.946.922.817.710.935.60.1
+ Deferred Tax4.42.2-22.06.43.84.810.3-8.20.42.512.5-10.3
Tax Expense34.226.720.425.631.249.757.214.618.113.448.1-10.2
Net Income116.5111.5188.675.7106.1131.1183.386.767.115.0147.9-9.0
+ Net Income — Continuing Ops116.5111.5188.675.7106.1131.1183.386.767.115.0147.9-9.0
+ Other Comprehensive Income-28.020.640.927.1-40.3-56.955.421.4-138.87.1-85.735.3
Total Comprehensive Income88.5132.1229.5102.865.874.2238.7108.1-71.722.162.226.3
Per Share
Basic EPS2.902.784.701.892.643.274.562.161.670.373.68-0.22
Diluted EPS2.902.774.691.882.643.264.562.151.670.373.67-0.22
Other Comprehensive Income — detail
+ Other Comprehensive Income55.421.4-138.87.1-85.735.3
+ Items NOT to be Reclassified to P&L-3.5-1.0-8.91.2-3.2-1.96.80.3-5.4-2.51.3-0.6
+ Tax on Items NOT to be Reclassified1.90.1-1.4-0.60.3-0.2
+ Tax on Items NOT to be Reclassified — alt tag-0.7-0.2-3.30.5-1.1-0.4
+ Items to be Reclassified to P&L-35.927.371.234.3-51.8-73.369.728.7-189.010.4-118.047.8
+ Tax on Items to be Reclassified19.27.5-54.21.4-31.312.1
+ Tax on Items to be Reclassified — alt tag-10.75.924.77.9-13.6-17.9
Per Share — as-filed variants
Basic EPS — Continuing Operations2.902.784.701.892.643.274.562.161.670.373.68-0.22
Diluted EPS — Continuing Operations2.902.774.691.882.643.264.562.151.670.373.67-0.22
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit642.9616.1714.1556.2654.4706.3783.0656.9672.1687.7803.4562.6
Gross Margin %70.6472.1977.8870.4373.4574.8476.9275.1273.8174.9977.5176.44
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)158.1141.9209.069.3137.3180.8240.5101.385.299.0202.0-5.7
− Exceptional Items (reconciliation)-7.4-3.70.032.00.00.00.00.00.0-70.6-6.0-13.5
Net Income Adj (tax-effected)122.2114.5188.651.8106.1131.1183.386.767.152.3152.4-2.7
EPS Adj3.042.854.701.292.643.274.562.161.671.293.79-0.07
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital402.0402.0402.0402.5402.5402.5402.5402.9402.9402.9402.9403.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.